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Abstract 
Background: adrenal tumor-to-liver uptake value (Tmx:Lmx) on 18F-FDG PET/CT is an accurate and 
reproducible PET parameter in the distinction betwen benign and malignant adrenal masses. The potential 
impact of steroid hormone secretion on 18F-FDG uptake is still debatable. The aim of this study was to evaluate 
this relationship. 
Methods: 2010-2015: 73 patients who underwent adrenalectomy for adrenocortical tumors [49 secreting/(SA) 
and 24 non-secreting/(NSA)] were retrospectively included in the study. Fourteen were malignant. All patients 
underwent hormonal evaluation, functional and anatomical imaging, Weiss scoring and Ki 67 evaluation. 
Results: malignant tumors exhibit higher SUVmax than benign tumors (median 7.75 vs 3.06 respectively, 
p<0.001) and Tmx:Lmx was 2.7 vs 1.17 for benign tumors, p<0.001. 
Tmx:Lmx was positively correlated to Weiss score (p<0.001). 
No significant difference was observed for Tmx:Lmx between SA and NSA overall (p=0.851), regardless of the 
subgroup of tumors analyzed. Tmx:Lmx was not correlated to tumor size (p<0.508) or 24h free urinary cortis l 
level (p<0.522). 
Conclusions: no correlation was observed between Tmx:Lmx and hormonal status, however the correlation 















benign from malignant adrenal lesions, irrespective of the hormone secretory status of the tumor. 18F-FDG 
PET/CT is a useful biomarker in the diagnosis of adrenal tumors, regardless of the secretion status.  
Introduction 
The characterization of adrenal masses by imaging is a critical step to determine appropriate treatmen and 
optimize prognosis. Adrenocortical carcinoma (ACC) is a rare and aggressive tumor for which comprehensiv  
surgical resection presents the only curative option [1]. 
Radioclinical presentation of adrenocortical masses can be very variable. The evaluation of adrenal masses 
requires, firstly, a complete clinical evaluation in addition to relevant biochemical and hormonal investigation. 
The presence of a steroid hypersecretion pattern (ACTH-independent Cushing syndrome, hyperaldosteronism 
and/or hyperandrogenism) enables the diagnosis of an adrenocortical tumor, which when associated with 
multiple secretion patterns and/or rapid clinical progression is highly suspicious for malignancy. In large tumors 
>4 cm and/or those with an unenhanced density >10UH, adrenal washout CT and/or adrenal MRI with chemical 
shift play a central role in the characterization of adrenal masses [2,3]. In recent years, 18F- Flurodeoxyglucose 
positron emission tomography (18F-FDG PET/CT) was found to provide additional information to anatomical 
imaging especially for patients with indeterminate masses on adrenal washout CT[2, 4, 5, 6, 7, 8, 9,10, 11]. 
 A recent prospective study has shown that the use of Tmx:Lmx was a reliable parameter in the evaluation of 
adrenal masses [12]. The molecular mechanisms involved in glucose uptake of ACC are currently unknown. 
Although the use of a cutoff value for Tmx:Lmx >1.5 is of high clinical value, ACC and sarcomas may exhibit 
lower uptake ratio and inversely benign lesions canbe hypermetabolic [4, 5, 13, 14, 15, 16 ]. A recent study 
from Patel et al. has evaluated the role of 18F-FDG PET/CT in the differentiation between nonfunctioning 
adrenal masses, aldosterone and cortisol secretion tumors. They showed that tumor uptake was higher in cortisol-
secreting adrenal masses than in nonfunctioning adren l masses and aldosterone-secreting tumors. They 
suggested that 18F-FDG PET/CT may be used for identifying cortisol-secreting adrenal masses and proposed to 
use 18F-FDG PET/CT for lateralization of secretion in cases with bilateral adrenal tumors [17].  The aim of this 

















Materials and Methods 
A cohort study was conducted in our Institution (Department of General Endocrine and Bariatric Surgery, La 
Conception University Hospital, Aix-Marseille University). Seventy-three patients that underwent 
adrenalectomy for benign and malignant adrenocortical masses [secreting (SA) and non-secreting (NSA) tumors] 
were retrospectively included from April 2010 to November 2015. All patients included had preoperative 18F-
FDG PET/CT for further tumor characterization (in the absence of typical features of adrenocortical adenoma on 
standard imaging with CT or MRI). 
Aldosterone-secreting adenomas (Conn adenoma) and pheochromocytomas were excluded from the analysis. 
 
Preoperative hormonal work-up 
All patients were investigated with biochemical tests (plasma ACTH-Cortisol cycle, free urinary cortisol/24h 
urine sample, serum deydroepiandrostenedione sulfate (DHEAS), serum 17-hydroxyprogesterone (17-HP), 
serum total testosterone, plasma and urinary metanephri es and normetanephrines, chromogranin A, plasma 
renin and aldosterone concentration) and conventional imaging (CT and/or MRI). Patients with an abnormal 
circadian cortisol rhythm or elevated urinary free-cortisol level or undetectable ACTH level, were evaluated by 1 
mg dexamethasone and standard dexamethasone suppression t ts (0.5 mg every six hours for 2 days). 
   
18F-FDG PET/CT protocol 
18F-FDG (4 MBq/Kg) was administered intravenously after fasting for 6 hours and acquisition of imaging data 
was performed at approximately 60 minutes post-injection. Blood glucose test was performed prior to scanning 
to confirm that all patients were normoglycemic.  
Attenuation correction was obtained by transmission imaging with computed tomography. Reconstructions in the 
transaxial, coronal and sagittal planes were performed. A region of interest (ROI) was drawn on the prima y 
tumor and on the VIII hepatic segment. Activity counts in the ROIs were normalized to injection doses p r 
kilogram of patient body weight (maximum standardize  uptake value: SUVmax). The SUVmax in the ROI on 
















Histology was considered the gold standard for the diagnosis of benign and malignant tumors. For adrenocortical 
tumors, the distinction between benign and malignant tumors was based on the Weiss score, adrenocortical 
carcinoma being defined by a Weiss score >3 [20, 21, 2 , 23]. 
For oncocytomas, tumors were classified according to the Bisceglia scoring system. [21, 24].  
In addition to pathological analysis, molecular status for LOH 17p13 status and expression of IGFII mRNA was 
obtained [22] and K67 was evaluated. 
 
Statistical Analysis 
Comparison of different quantitative parameters betwe n benign and malignant masses were performed using 
Mann-Whitney U test. Correlation studies were evaluated with Spearman and Pearson correlation. For 
comparison between continuous and ordinal qualitative variables the Jonckheere-Terpstra test was used.




Of 73 patients included in our data analysis 18 were male and 55 were female with a mean age of 52 years (15-
74 years) at the time of surgery. 
Forty-nine masses were SA (67.1%) and 24 NSA (32.9%). Fifty-nine were benign (80.8%) and 14 malignant 
were masses (19.2%). Of the benign masses, 20 were non-secreting (27.39%) and the remaining 39 were 
secreting (53.42%). Of the malignant masses 4 were non-secreting (5.47%) and 10 were secreting (13.69%) 
[tab.1].  
There was no significant difference in Tmx:Lmx betwen the SA and NSA (median of  1.26 for NSA (range 















On subgroup analysis, the median ratio of benign non-secreting tumors (BNSA) was 1.2 (range 5 - 0.5) with no 
difference when compared with benign secreting tumors (BSA): median ratio 1.17 (range 2.7 - 0.6), (p=0.901). 
The median ratio was 2.7 for both malignant subgroups (p=0.945): 4 malignant NSA (MNSA) (range 17.6 - 1.3) 
and of 10 malignant SA (MSA) (range 5.4 - 1.65).  
 
Determinants of 18F-FDG uptake 
There was a significant positive correlation between Tmx:Lmx and Weiss score (correlation coefficient: 0.6; 
p<0.001, Jonckheere-Terpstra test) [Fig.2].  
The correlation between Tmx in benign vs malignant tumors (median of 3.06 vs 7.75) and Tmx:Lmx of this 
group (1.17 vs 2.7) were strongly significant (p<0.001). 
There was no significant correlation between Tmx:Lmx and tumor diameter (coefficient correlation: 0.07; p< 
0.508, Chi-square Pearson test); no correlation was observed between Tmx:Lmx and free urinary cortisol/24h 
(coefficient correlation: 0.07; p<0.522, Spearman test) and there was no significant difference between Tmx of 
SA and NSA (median 3.3 for SA and 3.98 for NSA; p 0.514, Mann-Whitney test).  
 
Discussion 
Considering that approximately 12% of adrenal tumors cannot be adequately characterized by CT and MRI [25], 
18F-FDG PET/CT may provide additional information for characterizing these indeterminate adrenal masses 
[26]. In the present study we failed to identify a correlation between Tmx:Lmx and hormonal secretion. This 
result was observed in the subgroups of benign SA and NSA and also between malignant SA and NSA. No 
correlation was also observed between ratio/size, ratio/free urinary cortisol/24h urine sample and between Tmx 
of SA and NSA. Conversely, we found a correlation between Tmx:Lmx and Weiss score (p<0.001) a finding 
which was previously described by Tessonier et al. [18]. 
The only reported experience relative to the relationship between adrenal masses and hormonal secretion 
concerns secretory status and Tmx. It is reported in a recent pilot study as a potential approach for lateralization 
in patients with bilateral adrenal masses. In their s ies the authors analyzed 9 nonfunctioning adenomas, 4 
Conn’ syndromes and 11 cortisol-hypersecreting adrenal masses including bilateral masses. The tumor size was 















secreting adrenocortical masses and 12 mm in Conn ade omas). They identified 16 cortisol-secreting masses 
with a higher average SUVmax (5.9) than 11 nonfunctio ing adrenocortical masses (4.2) or than 5 Conn 
adenomas (3.2); no correlation between tumor size and Tmx was observed [17] as in our study. The authors 
demonstrated that the 18F-FDG uptake in cortisol-secreting tumors is higher than in nonfunctioning adrenal 
masses, in contrast with our experience. This result could be encouraging in the management of bilateral 
functional adrenal masses and with diagnostic and therapeutic difficulties (lateralization). However, in their 
series Tmx alone was analyzed. 
A qualitative approach to 18F-FDG PET/CT analysis has been advocated by Boland et al. in an analysis of 150 
patients who underwent to 18F-FDG PET/CT to evaluate an adrenal mass.  They report d that qualitative analysis 
(visual assessment) of 18F-FDG PET/CT images was a highly accurate way to differentiate benign from 
malignant adrenal masses when compared to the quantitative analysis provided by Tmx:Lmx and proposed that 
qualitative analysis alone could be sufficient to accurately characterize adrenal lesions [6, 7]. 
Certainly quantitative analysis using Tmx or Tmx:Lmx can be influenced by multiple patient and technical 
factors including body habitus, glycemia levels, varying times between radionuclide injection and imaging and 
image reconstruction methods [6, 27]. 
Furthermore the mean SUV may be influenced by size, hape and placement of regions of interest and maximal 
SUV by reconstruction method used [6]. 
Although the estimation of SUVmax is hampered to approximations and simplifications, it was found to be
lower affected by partial volume effect compared to other PET-derived indices. In the recent years PERCIST has 
been proposed for assessment of response to therapies but has not been evaluated for disease characteriz tion 
and head-to head comparison with histological findings [28].  
The use of more sensitive cameras and more precise SUV measurements has enhanced the role of quantitative 
PET analysis. Our results support the use of Tmx:Lm with specific cut-off values for differentiating benign 
from malignant adrenal masses, regardless of secretion status [5, 25]. 
In our series, the analyzed cohort differs from previous studies. We included patients with only one uilateral 
adrenal mass and we excluded patients with primary hyperaldosteronism. All the patients had adrenal masses >2 















In contrast with Pattel et al. [17] no correlation was found between Tmx or Tmx:Lmx and hormonal statu. This 
result could be explained by the differences in the study population.  
As already mentioned we analyzed 73 patients with cortisol secreting and non-secreting masses. In their study 
Pattel [17] et al. analyzed 24 patients including bilateral masses. 
Our data confirms the role and utility of 18F-FDG PET/CT in the distinction between benign and malignant 
tumors. 
The conflicting data pertaining to 18F-FDG PET/CT uptake in functional/secreting adrenal lesions may relate to 
the presence of confounding patient or technical factors that may influence 18F-FDG metabolism. 
 At present the correlation between 18F-FDG PET/CT uptake and adrenal tumor cortisol secretion is not certain 
and it should not lead to use of 18F-FDG for definitive interpretation of the functional status of an adrenal tumor. 
Furthermore, to date, secretion status should not ifluence the interpretation of SUV ration in predicting 
malignancy. 
In our longstanding experience in adrenal imaging ad the present results, we still consider that Tmx:L x 
remains more reliable than Tmx alone for disease characterization and can be extrapolated in clinical routine to 
various PET camera, without standardization. 
In the near future, the potential role of radiomics together with in vivo MR spectroscopy should be investigated 
in adrenal masses of various origin and secretory profile in order to potentially improve disease characterization 
in the preoperative work-up of patients. This integrative approach should provide crucial information for
assessment of risk stratification that can help the surgeons towards the most appropriate (personalized) surgical 
approach to be performed in a given situation. 
 
Conclusions 
18F-FDG PET/CT is a reliable imaging modality to distinguish benign from malignant adrenal masses especially 
by the measurement of Tmx:Lmx. Our study shows that t ere is no significant correlation between Tmx:Lmx on 
18F-FDG PET/CT and hormonal status, regardless of the benign or malignant nature of the tumor. To date, th  
knowledge of the hormonal status should not modify 18F-FDG uptake interpretation and therefore management 
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• The characterization of adrenal masses by imaging is a critical step to determine appropriate treatment and 
optimize prognosis. 
• 18F-FDG PET/CT is found to provide additional information to anatomical imaging especially for patients with 
indeterminate masses on adrenal washout CT but his role in the differentiation between nonfunctioning and 
functioning adrenal masses has recently been hypothesized.  
• In our analysis 18 F-FDG PET/CT is a reliable imaging modality to distinguish benign from malignant adrenal 
masses especially by the measurement of Tmx:Lmx (ratio). 
• In our experience there was no significant difference in Tmx:Lmx between the secreting and non-secreting 
adrenal masses regardless of the benign or malignant nature of the tumor but a significant positive correlation 
between Tmx:Lmx and Weiss score has been found confirming the relationship between high ratio and 
aggressiveness.  
• The correlation between ratio, malignancy and Weiss score confirm the utility of 18F-FDG PET/CT for the 
differentiation of benign from malignant adrenal lesions, irrespective of the hormone secretory status of the 
tumor. 
 
 
 
